Peripheral blood progenitor cell collection after epirubicin, paclitaxel, and cisplatin combination chemotherapy using EPO-based cytokine regimens: A randomized comparison of G-CSF and sequential GM-/-CSF

Transfusion

Volumn 41, Issue 5, 2001, Pages 674-680

  Perillo, Alessandro ^a   Pierelli, Luca ^a   Scambia, Giovanni ^a   Serafini, Riccardo ^a   Paladini, Umberto ^a   Salerno, Maria Giovanna ^a   Bonanno, Giuseppina ^a   Fattorossi, Andrea ^a   Leone, Giuseppe ^a   Mancuso, Salvatore ^a   Menichella, Giacomo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOKINE; EPIRUBICIN; MIELOGEN; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; APHERESIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; INFUSION; OVARY CARCINOMA; RANDOMIZED CONTROLLED TRIAL; STEM CELL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; EPIRUBICIN; ERYTHROPOIETIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 17944372437     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41050674.x     Document Type: Article

References (47)

1. Current issues in high-dose chemotherapy and stem cell support
2. Optimization of peripheral blood stem cell mobilization
3. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long-term results
4. Early lympho-hemopoietic recovery after autografting using peripheral blood stem cells in acute non-lymphoblastic leukemia
5. Peripheral blood stem cell collection and use in Hodgkin's disease. Comparison with marrow in autologous transplantation
6. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants
7. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor
8. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor
9. Effect of peripheral-blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy
10. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy
11. Defining a therapeutic dose of peripheral blood stem cells
12. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation
13. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma
14. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients
15. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients
16. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy
17. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide treated patients: Enhancement by intravenous recombinant human granulocyte macrophage colony stimulating factor
18. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: Results of a randomized comparison
19. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia
20. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor (rhG-CSF) and erythropoietin (rhEPO) in severe aplastic anemia
21. Treatment of the anemia of myelodisplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erytropoietin
22. The combination of erythropoietin and granulocyte colony stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation
23. Growth factor administration following autologous peripheral blood progenitor cell transplantation
24. Cytokine-mobilized peripheral blood progenitor cells
25. Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers
26. Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony stimulating factor to humans
27. Rapid hematopoietic recovery after multycycle high-dose chemotherapy: Enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor
28. Synergistic effects between GM-CSF and G-CSF or M-CSF on highly enriched human marrow progenitor cells
29. Combinations of colony-stimulating factors promote enhanced proliferative potential in enriched granulocyte-macrophage colony-forming cells
30. Randomized comparison of G-CSF+GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: Effects on hematopoietic recovery after high-dose chemotherapy
31. Innovations in allogeneic stem-cell transplantation
32. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation
33. Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs a combination of both
34. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors
35. Randomized trial of filgrastim, sargramostin, or sequential sargramostin and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells
36. Evaluation of a novel automated protocol for the collection of peripheral blood stem cells mobilized with chemotherapy or chemotherapy plus G-CSF using the Fresenius AS104 cell separator
37. Harvesting of peripheral blood progenitor cells with different programmes of discontinuous flow systems
38. low/- precursors
39. Factors affecting the efficiency of collection of CD34-positive peripheral blood cells by a blood cell separator
40. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a phase I and II clinical trial
41. Decreased erythropoietin response in patients with the anemia of cancer
42. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients
43. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis
44. Erythropoietin treatment of anemia associated with multiple myeloma
45. Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo
46. Erythropoietin for mobilization of circulating progenitor cells in patients with previously treated relapsed malignancies
47. Expansion of granulocyte colony-stimulating factor/chemotherapy-mobilized hematopoietic progenitors: Role of granulocyte-macrophage colony-stimulating factor/erythropoietin hybrid protein (MEN11303) and interleukin-15